Impact of bladder neck involvement on progression in patients with primary non-muscle invasive bladder cancer: A prospective validation study

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 1, 2014, Pages 38.e29-38.e36

  Kobayashi, Shuichiro ^a   Fujii, Yasuhisa ^a   Koga, Fumitaka ^a   Yokoyama, Minato ^a   Ishioka, Junichiro ^a   Matsuoka, Yoh ^a   Numao, Noboru ^a   Saito, Kazutaka ^a   Masuda, Hitoshi ^a   Kihara, Kazunori ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Bladder neck; Carcinoma; Progression; Urinary bladder; Urinary bladder neoplasms

Indexed keywords

AGED; ARTICLE; BLADDER NECK; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; FEMALE; FOLLOW UP; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; URETHRA CARCINOMA; VALIDATION STUDY;

BLADDER NECK; CARCINOMA; PROGRESSION; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

AGED; CARCINOMA, TRANSITIONAL CELL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84890787048     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.04.001     Document Type: Article

References (22)

1. Kirkali Z., Chan T., Manoharan M., Algaba F, Busch C, Cheng L., et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005, 66:4-34.
2. Saad A., Hanbury D.C., McNicholas T.A., Boustead G.B., Morgan S., Woodman A.C. A study comparing various noninvasive methods of detecting bladder cancer in urine. BJU Int 2002, 89:369-373.
3. Schrier B.P., Hollander M.P., van Rhijn B.W., Kiemeney L.A., Witjes J.A. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol 2004, 45:292-296.
4. Fujii Y., Fukui I., Kihara K., Tsujii T, Ishizaka K, Kageyama Y, et al. Significance of bladder neck involvement on progression in superficial bladder cancer. Eur Urol 1998, 464-468.
5. Sylvester R.J. Natural history, recurrence, and progression in superficial bladder cancer. Scientific World Journal 2006, 6:2617-2625.
6. Herr H.W., Badalament R.A., Amato D.A., Laudone V.P., Fair W.R., Whitmore W.F. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J Urol 1989, 141:22-29.
7. Herr H.W., Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol 2003, 169:1706-1708.
8. Orsola A., Palou J., Xavier B., Algaba F., Salvador J., Vicente J. Primary bladder carcinoma in situ: assessment of early BCG response as a prognostic factor. Eur Urol 1998, 33:457-463.
9. Sylvester R.J., van der Meijden A.P., Oosterlinck W., Witjes J.A., Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006, 49:466-475.
10. Stephenson W.T., Holmes F.F., Noble M.J., Gerald K.B. Analysis of bladder carcinoma by subsite. Cystoscopic location may have prognostic value. Cancer 1990, 66:1630-1635.
11. Kurth K.H., Denis L., Bouffioux C., Sylvester R., Debruyne F.M., Pavone-Macaluso M., et al. Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer 1995, 31A:1840-1846.
12. Sciarra A., De Matteis A., Mariotti G., Voria G., Lucera R., Di Silverio F. Histopathological aspects of transitional cell carcinoma of the bladder: analysis of 20 years experience. Int J Urol 2004, 11:467-475.
13. Millan-Rodriguez F., Chechile-Toniolo G., Salvador-Bayarri J., Palou J., Vicente-Rodriguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000, 163:73-78.
14. Vukomanovic I, Colovic V, Soldatovic I, Hadzi-Djokic J. Prognostic significance of tumor location in high-grade non-muscle-invasive bladder cancer. Med Oncol, 2012;29:1916-20.
15. Segal R., Yafi F.A., Brimo F., Tanguay S., Aprikian A., Kassouf W. Prognostic factors and outcome in patients with T1 high-grade bladder cancer: can we identify patients for early cystectomy?. BJU Int 2012, 109:1026-1030.
16. Pettus J.A., Al-Ahmadie H., Barocas D.A., Koppie T.M., Herr H., Donat S.M., et al. Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy. Eur Urol 2008, 53:370-375.
17. Nguyen M.M., Lieu D.K., deGraffenried L.A., Isseroff R.R., Kurzrock E.A. Urothelial progenitor cells: regional differences in the rat bladder. Cell Prolif 2007, 40:157-165.
18. van der Horst G, Bos L, van der Pluijm G. Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma. Mol Cancer Res, 2012;10:995-1009.
19. Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pineiro L, Ojea A, et al. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: external validation of the EORTC risk tables. Eur Urol 2011;60:423-30.
20. Sylvester R.J., van der M.A., Lamm D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002, 168:1964-1970.
21. Marugame T., Kaneko S. Comparison of bladder cancer mortality in five countries: France, Italy, Japan, UK and USA from the WHO Mortality Database (1960-2000). Jpn J Clin Oncol 2005, 35:357-360.
22. Matsuda T., Katanoda K. Comparison of time trends in bladder cancer incidence (1973-1997) in East Asia, Europe and USA, from Cancer Incidence in Five Continents Vol. IV-VIII. Jpn J Clin Oncol 2008, 38:85-86.